Nothing Special   »   [go: up one dir, main page]

EP3968985A4 - Kombinationstherapien mit bispezifischen anti-egfr/c-met-antikörpern und egfr-tyrosinkinase-inhibitoren der dritten generation - Google Patents

Kombinationstherapien mit bispezifischen anti-egfr/c-met-antikörpern und egfr-tyrosinkinase-inhibitoren der dritten generation Download PDF

Info

Publication number
EP3968985A4
EP3968985A4 EP20806609.2A EP20806609A EP3968985A4 EP 3968985 A4 EP3968985 A4 EP 3968985A4 EP 20806609 A EP20806609 A EP 20806609A EP 3968985 A4 EP3968985 A4 EP 3968985A4
Authority
EP
European Patent Office
Prior art keywords
egfr
tyrosine kinase
kinase inhibitors
combination therapies
bispecific anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20806609.2A
Other languages
English (en)
French (fr)
Other versions
EP3968985A1 (de
Inventor
Sylvie Laquerre
Matthew Lorenzi
Sheri MOORES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
Publication of EP3968985A1 publication Critical patent/EP3968985A1/de
Publication of EP3968985A4 publication Critical patent/EP3968985A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20806609.2A 2019-05-14 2020-05-14 Kombinationstherapien mit bispezifischen anti-egfr/c-met-antikörpern und egfr-tyrosinkinase-inhibitoren der dritten generation Pending EP3968985A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
EP3968985A1 EP3968985A1 (de) 2022-03-23
EP3968985A4 true EP3968985A4 (de) 2023-07-26

Family

ID=78716450

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20806609.2A Pending EP3968985A4 (de) 2019-05-14 2020-05-14 Kombinationstherapien mit bispezifischen anti-egfr/c-met-antikörpern und egfr-tyrosinkinase-inhibitoren der dritten generation

Country Status (12)

Country Link
EP (1) EP3968985A4 (de)
JP (1) JP2022531980A (de)
KR (1) KR20220010731A (de)
CN (1) CN113840601A (de)
AU (1) AU2020275272A1 (de)
BR (1) BR112021022828A2 (de)
CA (1) CA3140360A1 (de)
EA (1) EA202193117A1 (de)
IL (1) IL287962A (de)
MA (1) MA55978A (de)
MX (1) MX2021013955A (de)
SG (1) SG11202112412QA (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194403A1 (en) * 2001-06-13 2003-10-16 Genmab, Inc. Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20170101475A1 (en) * 2012-11-21 2017-04-13 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
US20170233497A1 (en) * 2010-04-20 2017-08-17 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716851A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and egfr antagonists
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194403A1 (en) * 2001-06-13 2003-10-16 Genmab, Inc. Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20170233497A1 (en) * 2010-04-20 2017-08-17 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US20170101475A1 (en) * 2012-11-21 2017-04-13 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov", 20 November 2015 (2015-11-20), XP093053109, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02609776> [retrieved on 20230609] *

Also Published As

Publication number Publication date
BR112021022828A2 (pt) 2022-04-12
KR20220010731A (ko) 2022-01-26
CA3140360A1 (en) 2020-11-19
JP2022531980A (ja) 2022-07-12
MA55978A (fr) 2022-03-23
EP3968985A1 (de) 2022-03-23
SG11202112412QA (en) 2021-12-30
EA202193117A1 (ru) 2022-02-11
IL287962A (en) 2022-01-01
AU2020275272A1 (en) 2021-12-02
CN113840601A (zh) 2021-12-24
MX2021013955A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EP3648753A4 (de) Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
EP3399968B8 (de) Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
EP3931224A4 (de) Kombinationstherapien und patientstratifizierung mit bispezifischen anti-egfr/c-met-antikörpern
IL278920A (en) ENTPD2 antibodies, combination therapies, and methods of using antibodies and combination therapies
EP3750920A4 (de) Bispezifischer antikörper in heterodimerer form ähnlich einer natürlichen anti-pd-1/anti-vegf-antikörperstruktur und herstellung davon
MY194328A (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use
EP4420727A3 (de) Bispezifische egfr/c-met-antikörper
PH12018500710A1 (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
WO2013164689A3 (en) Humanized pan-her antibody compositions
PH12020550055A1 (en) Antibodies that bind egfr and cmet
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
EP3752180A4 (de) Verfahren zur behandlung von krebs mit anti-pd-1-antikörpern
TN2019000161A1 (en) Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
WO2017035430A3 (en) Anti-alk antibodies and methods for use thereof
SG10201801219VA (en) Anti-HER2 Antibodies
WO2015179737A3 (en) Treatment of eosinophil or mast cell related disorders
EP3328426B8 (de) Behandlung von patienten mit diagnostiziertem duktalen adenokarzinom des pankreas mit monoklonalen antikörpern gegen den epidermalen wachstumsfaktor rezeptor (egfr)
EP3672635A4 (de) Monoklonale antikörper gegen pathologisches alpha-synuclein und verfahren zur verwendung davon
EP3998286A4 (de) Vierwertiger symmetrischer bispezifischer antikörper
EP4004053A4 (de) Bispezifischer anti-egfr/anti-4-1bb-antikörper und verwendung davon
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
EP4061851A4 (de) Verfahren zur krebsbehandlung unter verwendung von anti-ox40-antikörpern in kombination mit pi3-kinase-delta-inhibitoren
EP3968985A4 (de) Kombinationstherapien mit bispezifischen anti-egfr/c-met-antikörpern und egfr-tyrosinkinase-inhibitoren der dritten generation
EP3765080A4 (de) Verbesserungen einer therapie für cd47-blockade durch egfr-antikörper

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20230623

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20230619BHEP

Ipc: C07D 413/14 20060101ALI20230619BHEP

Ipc: A61K 31/395 20060101ALI20230619BHEP

Ipc: A61K 31/5355 20060101ALI20230619BHEP

Ipc: A61K 31/4155 20060101AFI20230619BHEP